Results for tag: "TNBC Drug"

Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express the estrogen receptor (ER), progesterone receptor (PR), or HER2/neu gene. Treatment for TNBC is typically more aggressive than other types of breast cancer, and is often treated with a combination of chemotherapy, radiation, and surgery. The TNBC drug market is a rapidly growing segment of the breast cancer drug market. It is estimated that the global TNBC drug market will reach $2.5 billion by 2027, driven by the increasing prevalence of breast cancer and the growing demand for targeted therapies. The market is expected to be driven by the increasing availability of novel therapies, such as immunotherapies and targeted therapies, as well as the increasing focus on personalized medicine. Some of the key players in the TNBC drug market include AstraZeneca, Pfizer, Merck, Novartis, and Roche. Show Less Read more